Immune checkpoint blockers (ICBs), monoclonal antibodies targeting cytotoxic T lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD-1), and programmed cell death ligand 1 (PD-L1) have been approved for the clinical management of cancer based on a series of phase III, randomized controlled trials [10]. The gene discussed is CD274; the disease is cancer.